Intra-Cellular Therapies, Inc. reports $44.1 million Q1 loss
The company generated $95.30 million in quarterly revenue
By USInMinutes
Published - May 04, 2023, 04:10 PM ET
Last Updated - Aug 26, 2024, 06:34 AM EDT
Intra-Cellular Therapies, Inc. [] has reported fiscal Q1 loss of $44.10 million.
On a per-share basis, the DE based company said its diluted earnings are $0.46.
The Pharmaceutical Preparations firm posted revenue of $95.30 million in this period.
